Prognostic role of inflammatory biomarkers from peripheral blood and clinical factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra-223) (BIO-Ra-223 study).

被引：0
|
作者：
Rebuzzi, Sara Elena
Bauckneht, Matteo
Signori, Alessio
Frantellizzi, Viviana
Rizzini, Elisa Lodi
Mascia, Manlio
Lavelli, Valentina
Stazza, Maria Lina
Licari, Maria
Donegani, Maria Isabella
Ponzano, Marta
Cavallini, Letizia
Laghi, Viola
Cindolo, Luca
Costa, Renato Patrizio
Spanu, Angela
Rubini, Giuseppe
Monari, Fabio
De Vincentis, Giuseppe
Fornarini, Giuseppe
机构：
[1] Univ Genoa, Med Oncol Unit 1, IRCCS Osped Policlin San Martino, Dept Internal Med & Med Specialties DiMI, Genoa, Italy
[2] IRCCS Osped Policlin San Martino, Nucl Med Unit, Genoa, Italy
[3] Sapienza Univ Rome, Dept Mol Med, Rome, Italy
[4] IRCCS Azienda Osped Univ Bologna, Radiat Oncol, Bologna, Italy
[5] Spirito Santo Hosp, Nucl Med Unit, Pescara, Italy
[6] Univ Bari Aldo Moro, Dept Nucl Med, Bari, Italy
[7] Univ Sassari, Dept Med Surg & Expt Sci, Nucl Med Unit, Sassari, Italy
[8] Univ Palermo, Biomed Dept Internal & Specialist Med, Nucl Med Unit, Palermo, Italy
[9] Univ Genoa, Dept Hlth Sci DISSAL, IRCCS Osped Policlin San Martino, Nucl Med, Genoa, Italy
[10] Univ Genoa, Dept Hlth Sci DISSAL, Genoa, Italy
[11] Alma Mater Studiorum Bologna Univ, Dept Expt Diagnost & Specialty Med, IRCCS Azienda Osped Univ Bologna, Radiat Oncol, Bologna, Italy
[12] Villa Stuart Private Hosp, Dept Urol, Rome, Italy
[13] Sapienza Univ Rome, Dept Radiol Sci Oncol & Anat Pathol, Rome, Italy
[14] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, Genoa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17026
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Clinical factors that are prognostic for survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223
    Al-Ezzi, E. M. M.
    Alqaisi, H. A.
    Iafolla, M.
    Sridhar, S.
    Sacher, A.
    Fallah-Rad, N.
    Jiang, D. M.
    Catton, C.
    Warde, P.
    Hamilton, R.
    Fleshner, N.
    Zlotta, A.
    Hansen, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S537 - S538
  • [32] Prognostic biomarkers in the use of radium-223 in patients with metastatic castration-resistant prostate cancer
    Vidal, M.
    Cardenas-Perilla, R.
    Delgado, A.
    Moron, S.
    Blair, J. L. Londono
    Vega, I.
    Ochoa, J. J. Correa
    Rojas, J.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (05): : 310 - 317
  • [33] Real-world utilization of radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A US tertiary oncology center analysis
    McKay, Rana R.
    Silver, Rebecca
    Bhak, Rachel
    Korves, Caroline
    Cheng, Mu
    Appukkuttan, Sreevalsa
    Simmons, Stacey J.
    Duh, Mei Sheng
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [34] Single-Institution Experience With Radium-223 Dichloride (Ra-223) for Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Cox, B. W.
    Wang, L.
    Bradley, T.
    Gu, B.
    Kelley, K.
    Potters, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S470 - S470
  • [35] Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)
    Sun, Y.
    Shi, H.
    Chen, C. -H.
    Lee, J. L.
    Kang, T. W.
    Park, S. H.
    Wu, T. L.
    Ng, Q. S.
    Keam, B.
    Wong, S. C. A.
    Tay, M. H.
    Ding, Q.
    Li, F.
    Ng, D. C. E.
    Liu, X.
    Zhang, Z.
    Guo, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 74
  • [36] Role of serum biomarkers of bone metabolism in metastatic castration-resistance prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): PRORADIUM study final results
    Romero Laorden, N.
    Lorente, D.
    Lozano Mejorada, R.
    Sanchez-Soler, N.
    De Velasco, G.
    Puente, J.
    Borrega, P.
    Gonzalez-Billalabeitia, E.
    Castillo-Morales, V.
    Hernandez, A.
    Fernandez-Freire, A.
    Lopez Campos, F.
    Villatoro, R.
    Fernandez Calvo, O.
    Anido, U.
    Lainez, N.
    Luque, R.
    Ros Martinez, S.
    Castro, E.
    Olmos, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S648 - S648
  • [37] Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer
    Parimi, Sunil
    Bondy, Suraya
    Tsang, Erica
    McKenzie, Michael Ross
    Bachand, Francois
    Aparicio, Maria
    Duncan, Graeme
    Sunderland, Katherine
    Olson, Robert Anton
    Pai, Howard Huaihan
    Alexander, Abraham Skaria
    LaPointe, Vincent
    Chi, Kim N.
    Tyldesley, Scott
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (10): : E311 - E316
  • [38] Sarcopenia assessment in men with metastatic castration-resistant prostate cancer (mCRPC) undergoing radium 223 (Ra223) therapy
    Khan, M.
    Carvajal, J. Briones
    Parshad, S.
    Emmenegger, U.
    ANNALS OF ONCOLOGY, 2020, 31 : S535 - S535
  • [39] The current evidence on prognostic factors in metastatic castration-resistant prostate cancer patients treated with Radium-223
    Maggi, Martina
    Gandaglia, Giorgio
    Rajwa, Pawel
    Martini, Alberto
    Marra, Giancarlo
    EAU YAU prostate Canc Working party
    MINERVA UROLOGY AND NEPHROLOGY, 2022, 74 (06): : 791 - 793
  • [40] Prognostic factors that affect survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223
    Al-Ezzi, Esmail Mutahar
    Alqaisi, Husam
    Picardo, Sarah
    Iafolla, Marco
    Sridhar, Srikala S.
    Sacher, Adrian G.
    Fallah-Rad, Nazanin
    Catton, Charles
    Warde, Padraig
    Hamilton, Robert James
    Fleshner, Neil Eric
    Zlotta, Alexandre
    Hansen, Aaron Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345